Background: both cognitive ability and cognitive decline have been shown to predict mortality in older people. As dementia, a major form of cognitive decline, has an established association with shorter survival, it is unclear the extent to which cognitive ability and cognitive decline predict mortality in the absence of dementia.
Introduction
Lower cognitive ability and greater decline in cognitive ability predict mortality in older people, even when controlling for other biomedical risk factors [1] [2] [3] [4] [5] [6] . A number of mechanisms may be responsible for the relationship. Lower cognition may contribute to a less healthy lifestyle, including diet, physical activity and treatment compliance [7] , and thus to poorer health outcomes. Alternatively, a common factor may cause both outcomes. Organ failure [8, 9] or the accumulation of cellular damage with ageing [10] , for example, could lead to both lower cognition and greater mortality.
Dementia, a major form of cognitive decline, is associated with a reduced lifespan [11] , so could be responsible for the relationship. Comparatively little research, however, has controlled for dementia. Whereas several studies have excluded participants with dementia at baseline [12] , the only study that excluded participants who subsequently developed dementia [13] found that poorer cognition still predicted mortality. This study, however, lacked a formal assessment for dementia, relying instead on a brief telephone screening test to assess cognition; did not control for depression, which affects both cognition and mortality [14] ; and did not examine whether decline in cognition over time predicted mortality. As such, it remains unclear the extent to which cognitive decline that does not meet the threshold of dementia predicts mortality.
To address these limitations, we examined predictors of mortality at 8 years in a population-based sample of older people without dementia. Participants completed detailed cognitive and medical assessments at 2-year intervals. We hypothesised that lower levels of cognition at baseline and greater decline in cognition would be associated with earlier mortality, even when excluding participants who subsequently developed dementia and controlling for depression and other risk factors.
Method Participants
The Sydney Memory and Ageing Study (MAS) is a longitudinal study of community-dwelling older adults in Sydney, Australia [15] . Participants aged 70-90 years were recruited from the electoral roll (registration is compulsory in Australia). To ensure that participants did not have pre-existing dementia or psychopathology, participants were excluded if they had a history of dementia, suspected dementia based on baseline assessment and consensus diagnosis from an expert panel, or a Mini-Mental State Examination (MMSE) score <24 adjusted for age, education and non-English-speaking background. Participants were also excluded if they had insufficient English to complete psychometric assessment, experienced psychotic symptoms or received a diagnosis of schizophrenia, bipolar disorder, multiple sclerosis, motor neuron disease, developmental disability or progressive malignancy. The baseline sample consisted of 1,037 participants. This study was approved by the Ethics Committees of the University of New South Wales and the South Eastern Sydney and Illawarra Area Health Service. Written informed consent was obtained from all participants.
Instruments and methods
The baseline assessment involved three parts. First, participants were interviewed over the telephone to collect demographic data, such as age, sex and education. Second, participants completed a detailed face-to-face assessment that consisted of a medical history, a medical examination and a neuropsychological examination. The medical history included questions about vascular diseases and risk factors such as hypertension, hypercholesterolaemia, smoking and diabetes. The medical examination assessed participants' height and weight, which were used to calculate body mass index (BMI); blood pressure and the time it took participants to complete a 6-m walk and stand from a seated position five times. Participants also completed a fasting blood test to assess cholesterol and glucose levels.
The neuropsychological examination included the MMSE [16] and a battery of neuropsychological tests. Attention/processing speed was assessed using DigitSymbol Coding [17] and Trail Making Test A [18] ; memory using Logical Memory Story A [19] , Rey Auditory Verbal Learning Test [18] and Benton Visual Retention Test [20] ; language using the Boston Naming Test [21] and Semantic Fluency [18] ; visuospatial ability using Block Design [17] ; and executive function using the Controlled Oral Word Association Test [18] and Trail Making Test B [18] . Raw test scores were transformed to z-scores using baseline means and SDs of a subgroup who had spoken English before 10 years of age and were classified as cognitively normal at baseline (n = 504). Domain scores were calculated by averaging the z-scores of component tests, which were then transformed to make the means of the cognitively normal subgroup 0 and the SDs 1. The global cognition score was calculated by averaging across domain scores and transforming the scores as before. Finally, participants completed several questionnaires, including the 15-item Geriatric Depression Scale [22] , and an inventory of current physical activity, which assessed the amount of time participants engaged in physical activity [23] .
Participants were reassessed at 2-year intervals. Decline in cognition was calculated by subtracting the global cognition score at 2 years from the global cognition score at baseline. At each assessment, a panel of specialist clinicians assessed whether participants met criteria for dementia (DSM-IV) based on all available information [24] . Data about participants' date and cause of death were obtained from the New South Wales Registry of Births, Deaths and Marriages 8 years after the study began.
Statistical analyses
Analyses using Cox proportional hazard model were performed to determine whether baseline variables predicted mortality. Predictors were entered in three stages: age, sex, cognition (global Z-score) and decline in cognition (over 2 years) were entered first, followed by depression, and then other biomedical risk factors, namely: BMI, current smoking, diabetes (defined as a history of diabetes or a fasting blood glucose level of 7.0 mmol/l or greater), hypercholesterolaemia (defined as a history of high cholesterol or a measured LDL cholesterol of 4.1 mmol/l or greater), hypertension (defined as a history of hypertension, a systolic pressure >139 mmHg or a diastolic pressure >89 mmHg), 6-m walk (time in seconds), sit-to-stand (time in seconds) and amount of physical activity (minutes/week). Missing data for continuous variables were handled using expectation-maximisation imputation (see Supplementary data, Appendix, available in Age and Ageing online). A post hoc analysis compared the odds of dying for participants whose cognitive decline was in the highest 0.5 SD with other participants.
To rule out dementia as a contributing factor, a sensitivity analysis was conducted excluding participants diagnosed with dementia in biannual assessments over the 8-year period or whose death certificate listed dementia as a cause of death. To rule out terminal drop-cognitive decline that often occurs immediately before death [1] [2] [3] [4] [5] -as a contributing factor, participants who died within 3 months of cognitive assessment were also excluded in this analysis.
Results
Participants' demographic characteristics are summarised in Table 1 (SD = 2.14) from baseline. At 2-year follow-up, 860 (82.9%) completed a second cognitive assessment. Both lower baseline cognition and greater decline in cognition over 2 years predicted earlier mortality when controlling for age and sex (Table 2 ). Decline in cognition over 2 years, but not baseline cognition, predicted earlier mortality when depression was included in the model. Decline in cognition remained a significant predictor when other biomedical risk factors were included in the model. Other significant predictors included older age, male sex, depression, diabetes, less physical activity and longer sit-to-stand time. Multicollinearity was not an issue (all variance inflation factors <1.6). Post hoc analysis revealed that participants whose cognitive decline was within the highest 0.5 SD had 1.80 greater risk of dying [95% CI: 1.24-2.63] compared with other participants.
Over the 8 years, 106 participants were diagnosed with dementia and a further 3 had dementia listed as a cause of death on their death certificate. Six participants died within 3 months of cognitive assessment. Decline in cognition, however, remained a significant predictor of mortality when excluding these participants (Supplementary data, Appendix, available in Age and Ageing online). Other predictors remained unchanged except that smoking was a significant predictor and diabetes was not when these participants were excluded.
Discussion
The findings confirm that decline in cognition in people without dementia predicts mortality. While consistent with previous research that has found a relationship between cognition and mortality [1] [2] [3] [4] [5] [6] 13] , the current study indicates that decline in cognition over time, rather than baseline levels, predicts mortality once depression is controlled for. The findings also suggest that this relationship holds even when excluding incident cases of dementia and controlling for other established biomedical risk factors. Of these, older age, male sex, diabetes, depression and poorer physical performance predicted shorter survival.
Decline in cognition may result from a number of pathophysiological processes [25] . It is therefore not surprising that it is associated with a greater risk for mortality than baseline levels of cognition, which can reflect stable intra-individual differences [26] . This possibility is consistent with other evidence that faster rates of cognitive decline are apparent at an intra-individual level over 8 years prior to death [26] . It is also consistent with previously published evidence that deceased older people have a faster pre-mortem cognitive decline relative to survivors who had similar baseline cognition [27] and that shorter time to death is associated with faster cognitive decline in genetically similar individuals [28] .
Given possible relationships between baseline levels and rates of change, both variables need to be considered in analyses. Change scores are also subject to measurement error, regression to the mean and practice effects, which can make it difficult to interpret small changes in an individual [29, 30] . Despite these limitations, however, decline in cognition appears to be a robust predictor of mortality at a population level.
Key points
• Decline in cognition over 2 years predicts mortality in older people without dementia.
• Baseline cognition did not predict mortality when depression and other biomedical risk factors were controlled for.
• Cognitive assessments of older people can predict longevity at a population level. Cognition at baseline and decline in cognition represent z-scores of global cognition and change in z-scores of global cognition, respectively. Sex represents the risk of mortality for females relative to males. Current smoking, diabetes, hypercholesterolaemia and hypertension were dichotomous variables based on current clinical guidelines; their derivation is described in the text. P-values in bold indicate significance at less than 0.05. 
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